Last reviewed · How we verify
Vehicle Ophthalmic Solution QID to BID
A vehicle ophthalmic solution formulation designed to be administered topically to the eye at varying frequencies (four times daily reduced to twice daily).
A vehicle ophthalmic solution formulation designed to be administered topically to the eye at varying frequencies (four times daily reduced to twice daily). Used for Ophthalmic indication (specific indication not specified in available information).
At a glance
| Generic name | Vehicle Ophthalmic Solution QID to BID |
|---|---|
| Sponsor | Aldeyra Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
This appears to be a formulation study or dose-optimization trial for an ophthalmic therapeutic agent. The notation 'QID to BID' suggests a dose-reduction or frequency-optimization protocol, moving from four times daily dosing to twice daily dosing. Without identification of the active pharmaceutical ingredient, the specific mechanism cannot be determined.
Approved indications
- Ophthalmic indication (specific indication not specified in available information)
Common side effects
Key clinical trials
- A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease (PHASE3)
- A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (PHASE2)
- A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease (PHASE2)
- The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease (PHASE3)
- Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis (PHASE2)
- Nesvategrast (OTT166) in Diabetic Retinopathy (DR) (PHASE2)
- Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: